目的：运用数据挖掘方法分析含“十八反”药物治中风病古今方剂配伍和治疗特点。方法：收集规范古代及近现代中风病方剂中含“十八反”反药组对的处方，运用关联规则对方剂进行高频药物挖掘，对方剂剂型、年代进行对应分析。结果：经整理获得古今中风病“十八反”反药同方方剂共173首，其中古代方剂111首，近现代方剂62 首。相反药对以半夏-附子使用最多，共76首。古今含“十八反”药物治疗中风方剂高频药物存在显著差异（P<0.05）。结论：古今治疗中风均重视治痰，但古方用药以天南星、川芎、全蝎、天麻、白附子、白僵蚕为主，偏于熄风通络化痰，病机方面重视痰瘀邪实；近现代方用药以甘草、茯苓、白术、陈皮为主，偏于益气健脾化痰，病机方面重视正气亏虚。

This study was aimed to analyze the characteristics of ancient and contemporary formulas containing "18 Incompatible Pairs of Drugs" for stroke treatment through the application of association rules and correspondence analysis. Ancient and contemporary prescriptions, which are listed in the "18 Incompatible Pairs of Drugs," for stroke treatment were collected and collated. Then, crucial drugs of these formulas were explored by using data mining methods as association rules. And correspondence of age and preparation of these prescriptions was also investigated. The results showed that there were in all 173 formulas which contain "18 Incompatible Pairs of Drugs" for stroke treatment, including 111 ancient formulas and 62 modern formulas. Altogether 76 formulas contain the pair "Rhizoma Pinelliae——Radix Aconiti Lateralis Preparata" ranking the first among all the "18 Incompatible Pairs of Drugs." It was concluded that the central drugs in stroke treatment are significantly different between ancient and modern formulas (P < 0.05). Both ancient and modern formulas paid great attention to phlegm syndrome. Main drugs of ancient formulas are Rhizoma Arisaematis, Rhizoma Ligustici Chuanxiong, Scorpio, Rhizoma Gastrodiae, Rhizoma Typhonii, Bombyx Batryticatus, and etc. Their effects are focused on promoting blood circulation and removing phlegm. They are aimed at syndromes of intermingled phlegm and blood stasis. The central drugs of modern formulas are Radix Glycyrrhizae, Poria, Rhizoma Atractylodis Macrocephalae, Pericarpium Citri Reticulatae , and etc. Their effects are concentrated on benefiting qi, invigorating spleen and removing phlegm. The focus is on the treatment of deficiency syndrome.

国家重点基础研究发展计划（“973 计划”）项目（2011CB505300-01）：基于“十八反”的中药配伍禁忌理论基础研究——基于“十八反”的中药配伍禁忌数据挖掘与知识发现研究，负责人：范欣生。